BioCentury | Jun 5, 2006
Finance

Cardiome chronicles

...events related to RSD1235. A. 6/25/01 - The company changes its name to Cardiome from Nortran...
BioCentury | Jun 25, 2001
Clinical News

Nortran preclinical data

...bioavailability equivalent to intravenous administration. Plasma levels of 2.7-3.8 ug/ml were achieved within 15-30 minutes. Nortran Pharmaceuticals Inc....
BioCentury | Apr 16, 2001
Clinical News

RSD1235: Began Phase I trial

Nortran Pharmaceuticals Inc. (TSE:NRT; NTRDF), Vancouver, B.C. Product: RSD1235 Business: Cardiovascular, Drug delivery Therapeutic category: Ion channel modulation Target: Ion channels Description: Ion channel modulator anti-arrhythmic Indication: Treat atrial arrhythmia End point: Safety and dose...
BioCentury | Feb 20, 2001
Company News

Nortran management update

Nortran Pharmaceuticals Inc. (VSE:NRT; NTRDF), Vancouver, B.C. Business: Cardiovascular, Neurological, Pulmonary Hired: Alan Ezrin as CSO and a director, formerly CSO at ConjuChem Inc. WIR Staff Cardiovascular Neurology Pulmonary...
BioCentury | Feb 5, 2001
Clinical News

Nortran preclinical data

...terminated 50 and 90 percent of atrial fibrillation, respectively, with no change in QT interval. Nortran Pharmaceuticals Inc....
BioCentury | Jan 22, 2001
Company News

Nortran cardiovascular news

...cough that did not show a statistically significant inhibition of cough (see BioCentury, Jan. 2). Nortran Pharmaceuticals Inc....
BioCentury | Jan 2, 2001
Clinical News

CP1: Phase II

...CP1 did not show a statistically significant inhibition of cough (see BioCentury, April 3, 2000). Nortran Pharmaceuticals Inc....
BioCentury | Oct 23, 2000
Company News

Nortran, AstraZeneca deal

...payment plus milestone payments and royalties, and retains rights to develop its other antiarrhythmic compounds. Nortran Pharmaceuticals Inc....
BioCentury | Apr 3, 2000
Clinical News

CP1: Began Phase II testing

Nortran Pharmaceuticals Inc . (CDNX:NRT; NTRDF), Vancouver, B.C. Product: CP1 Business: Neurological Therapeutic category: Neurotransmission Target: Peripheral nerve endings in the airway Description: Inhaled small molecule that blocks the initiation of cough Indication: Treat chronic idiopathic...
BioCentury | Mar 28, 2000
Clinical News

Nortran starts Phase II

Nortran (CDNX:NRT; NTRDF) began placebo-controlled Phase II testing to examine the efficacy of CP1 inhaled small molecule that blocks the initiation of cough in reducing heightened sensitivity to tussive stimuli, such as airborne particles, cold...
Items per page:
1 - 10 of 35
BioCentury | Jun 5, 2006
Finance

Cardiome chronicles

...events related to RSD1235. A. 6/25/01 - The company changes its name to Cardiome from Nortran...
BioCentury | Jun 25, 2001
Clinical News

Nortran preclinical data

...bioavailability equivalent to intravenous administration. Plasma levels of 2.7-3.8 ug/ml were achieved within 15-30 minutes. Nortran Pharmaceuticals Inc....
BioCentury | Apr 16, 2001
Clinical News

RSD1235: Began Phase I trial

Nortran Pharmaceuticals Inc. (TSE:NRT; NTRDF), Vancouver, B.C. Product: RSD1235 Business: Cardiovascular, Drug delivery Therapeutic category: Ion channel modulation Target: Ion channels Description: Ion channel modulator anti-arrhythmic Indication: Treat atrial arrhythmia End point: Safety and dose...
BioCentury | Feb 20, 2001
Company News

Nortran management update

Nortran Pharmaceuticals Inc. (VSE:NRT; NTRDF), Vancouver, B.C. Business: Cardiovascular, Neurological, Pulmonary Hired: Alan Ezrin as CSO and a director, formerly CSO at ConjuChem Inc. WIR Staff Cardiovascular Neurology Pulmonary...
BioCentury | Feb 5, 2001
Clinical News

Nortran preclinical data

...terminated 50 and 90 percent of atrial fibrillation, respectively, with no change in QT interval. Nortran Pharmaceuticals Inc....
BioCentury | Jan 22, 2001
Company News

Nortran cardiovascular news

...cough that did not show a statistically significant inhibition of cough (see BioCentury, Jan. 2). Nortran Pharmaceuticals Inc....
BioCentury | Jan 2, 2001
Clinical News

CP1: Phase II

...CP1 did not show a statistically significant inhibition of cough (see BioCentury, April 3, 2000). Nortran Pharmaceuticals Inc....
BioCentury | Oct 23, 2000
Company News

Nortran, AstraZeneca deal

...payment plus milestone payments and royalties, and retains rights to develop its other antiarrhythmic compounds. Nortran Pharmaceuticals Inc....
BioCentury | Apr 3, 2000
Clinical News

CP1: Began Phase II testing

Nortran Pharmaceuticals Inc . (CDNX:NRT; NTRDF), Vancouver, B.C. Product: CP1 Business: Neurological Therapeutic category: Neurotransmission Target: Peripheral nerve endings in the airway Description: Inhaled small molecule that blocks the initiation of cough Indication: Treat chronic idiopathic...
BioCentury | Mar 28, 2000
Clinical News

Nortran starts Phase II

Nortran (CDNX:NRT; NTRDF) began placebo-controlled Phase II testing to examine the efficacy of CP1 inhaled small molecule that blocks the initiation of cough in reducing heightened sensitivity to tussive stimuli, such as airborne particles, cold...
Items per page:
1 - 10 of 35